Member Info for Timster

we know a bit more about Mologic then and it appears they are slightly behind or level with our development path.

Great day today and so much news incoming .....

Rumour first then solid news to come on so many fronts:
-AVA6000
-BAMS validation
-More manufacturing capacity for LFT
-LFT pilot batch into validation
-LFT CE marking

No news tomorrow, just strong rumours sir Al is going to save the world !!!

I reckon we open tomorrow at £1.64

16 quid close of play Friday then ;)

.

Seems fairly obvious that the UK government are doing everything they can now to help avacta through to manufacturing and distributing the holy grail of tests.
Very exciting weeks and months to come

The weight of evidence suggests validation is a given. The test works, we've been told this numerous times it uses the same Affimers as the ELISA and BAMS tests.
Challenge is manufacturing as stated in the latest presentation we will never make enough for demand, what a position to be in.

-Avacta is expanding its inhouse Affimer production facilities and putting in place very large scale contract manufacturing partners; Affimer and nor will nitrocellulose strip. Avacta supply will not be a limiting factor

-has partnered with BBI Solutions and Abingdon Health to date, who can manufacture several millions of lateral flow test strips per month.

-UK strip manufacturing capacity needs to be scaled rapidly to address the anticipated volume requirements and additional capacity is being put in place overseas.
-Kit assembly is a challenge and partners in the UK have been identified and additional resources overseas are being put in place.

-Detailed discussions with regulatory authorities, governments and healthcare providers are ongoing but are strictly confidential.

Looking more and more like Affimers are required for a successful saliva test. MASSIVE for Avacta not only with our own test but OEM deals for the use of Affimers....

https://bit.ly/36q0uJz

thats the directors talk Q&A

https://avacta.com/wp-content/uploads/2020/09/Avacta-Group-plc-Interim-Results-September-2020-v2.pdf

without the asterisk's

Agree'd it feels like we are on the verge of greatness!

perhaps Affimers entering the mainstream testing realms and also human trials with the neutraliser will be one of the medical breakthroughs of this era... exciting times

early Friday FOMO :)

https://avacta.com/wp-content/uploads/2020/09/Avacta-Group-plc-Interim-Results-September-2020-v2.pdf

slide 28:
OEM deals have the potential to expand the commercial opportunity for Avacta

who doesn't love an inflection point!

• AVA6000 pro-doxorubicin aiming for CTA submission 4Q20
• Partnered programmes all progressing well plus expansion of LG Chem agreement to include Affimer XTTM and
expansion of Daewoong partnership to cover SARS-CoV-2 neutralising therapies.
• In-house Affimer immunotherapy and pre|CISION pro-drug pipeline expansion underway.
• Diagnostics: good progress in bringing COVID-19 lateral flow antigen tests to market plus multiple
additional COVID and core-business partnering opportunities.
• Completion of first pilot batch of lateral flow tests is the next key milestone that will define time to market
much more clearly.
• Good engagement with authorities, regulators and healthcare providers.
• BAMS clinical evaluation now beginning after long delays in the sample access process.
• Significant additional third party commercial interest in spike protein Affimer binders (including several global
IVD companies, bioprocessing companies and research reagents suppliers).

if you are wobbly, "a bit concerned", "slightly worried" or a little bit scared then have a good read through the last presentation again:
https://avacta.com/wp-content/uploads/2020/09/Avacta-Group-plc-Interim-Results-September-2020-v2.pdf

they need to read the latest presentation. Then they will know saliva works with Affimer's
https://avacta.com/wp-content/uploads/2020/09/Avacta-Group-plc-Interim-Results-September-2020-v2.pdf

slide 28

You'll see a massive rise tomorrow! Well played Dan...

That reporter needs to do some proper research into Avacta

On a blue day nothing from the usual suspects. Which is why filtering them is the way forward.

Nowhere near, with the inflection points we have